The potential of reducing BW and improving insulin sensitivity suggests a possible clinical role of PPARγ antagonists in treating obesity and type 2 diabetes (Yamauchi et al., 2001; Rieusset et al., 2002; Nakano et al., 2006). The gene discussed is INS; the disease is type 2 diabetes mellitus.